2-[(1-Phenyl-1H-tetrazole-5-ylthio)acetyl]naphthalene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[(1-Phenyl-1H-tetrazole-5-ylthio)acetyl]naphthalene
• 英文别名: 1-naphthalen-2-yl-2-(1-phenyltetrazol-5-yl)sulfanylethanone
• 化学式: C₁₉H₁₄N₄OS
• 分子量: 346.412
• InChiKey: IQKZQBMZAKENSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  86
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(1-Phenyl-1H-tetrazole-5-ylthio)acetyl]naphthalene 在 chromium(VI) oxide 、 高碘酸 作用下， 以 乙腈 为溶剂， 生成 1-naphthalen-2-yl-2-(1-phenyl-1H-tetrazole-5-sulfonyl)ethanone
  参考文献：
  名称：

  β-羰基苯基四唑砜的实用合成及其有机催化反应性研究

  摘要：

  显示了可用于一系列对映选择性反应的 β-羰基苯基四唑砜的实际合成。芳基、烷基和酯羰基化合物都被证明是有效合成的，两步生成的产物产率高达 >99%。在此过程中，不需要特别注意条件或通过色谱法进行费力的纯化。此外，X 射线晶体学、动力学研究以及 NMR 和 IR 研究提供了对这些化合物在有机催化中的反应性的深入了解。

  DOI：

  10.1002/ejoc.201001426
• 作为产物：
  描述：

  1-苯基-5-巯基四氮唑 、 2-溴代-2-乙酰基萘 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-[(1-Phenyl-1H-tetrazole-5-ylthio)acetyl]naphthalene
  参考文献：
  名称：

  α,β-不饱和醛的不对称有机催化形式炔化和烯基化

  摘要：

  提出了一种使用基于 β-酮杂环砜的新型化学方法对 α、β-不饱和醛进行正式炔基化和烯基化的高度立体选择性有机催化一锅法。有机催化步骤由脯氨醇衍生物催化，并允许形成重要的光学活性化合物。基于 Smiles 重排的新发展，通过与 Julia-Kocienski 反应平行的过程，对 β-酮杂环砜部分进行了进一步的转化，产生了 β-炔基化醛和 3-链烯基化醇。各种光学活性炔烃和烯烃的合成证明了这两种转化的范围。此外，还进行了醛和醇官能度的不同转化。最后，

  DOI：

  10.1021/ja903920j

文献信息

• Thermolysis of β-hydroxysulfides bearing several heteroaromatics
  作者：Nobuhiko Yamada、Masayoshi Mizuochi、Hiroyuki Morita

  DOI：10.1016/j.tet.2007.01.043

  日期：2007.4

  Thermolyses of beta-hydroxysulfides 2, bearing groups, such as 2-benzothiazolyl and 4-(4-methyl)-4H-1,2,4-triazolyI groups, were studied and found to afford the corresponding substituted styrenes 5 and hydroxy heteroaromatics in good yields, respectively. The product distribution change in the course of the thermolysis of 2a was also studied. The olefin products 5a were considered to be formed by the thermal desulfurization of the corresponding thiiranes 4a initially formed via the five-membered spiro intermediate 6a. (c) 2007 Elsevier Ltd. All rights reserved.
• Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies
  作者：Selvam Chitra、Nidhin Paul、Shanmugam Muthusubramanian、Paramasivam Manisankar、Perumal Yogeeswari、Dharmarajan Sriram

  DOI：10.1016/j.ejmech.2011.07.046

  日期：2011.10

  A series of 3-heteroarylthioquinoline derivatives has been synthesized by the Friedlander annulation of 2-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]-1-aryl-1-ethanone/2-(1,3-benzothiazol-2-ylsulfanyl)-1-aryl-1-ethanone/1-aryl-2-[(2-phenyl-2H-1,2,3,4-tetraazol-5-yl)sulfanyl]-1-ethanone with 2-aminobenzophenone in good yields using YbCl3 as the catalyst. These compounds have been screened for their in vitro activity against Mycobacterium tuberculosis H37Rv (MTB) and among the 21 compounds screened, 2-[2-(4-bromophenyl)-4-phenyl-3-quinolyl]sulfanyl-5-methyl-1,3,4-thiadiazole (5d) and 2-[2-(4-chlorophenyl)-4-phenyl-3-quinolyl]sulfanyl-5-methyl-1,3,4-thiadiazole (5c) were found to be the most active compounds with MIC of 3.2 and 3.5 mu M respectively against MTB. The cytotoxic effects against mouse fibroblasts (NIH 3T3) in vitro were evaluated for 5c and 5d, which displayed no toxic effects (IC50 > 1000 mu M) against the mouse fibroblast cell line NIH 3T3. (C) 2011 Elsevier Masson SAS. All rights reserved.
• [EN] 1,5-SUBSTITUTED TETRAZOLES AS THERAPEUTIC COMPOUNDS<br/>[FR] TETRAZOLES 1,5-SUBSTITUÉS EN TANT QUE COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV EDINBURGH

  公开号：WO2007029021A1

  公开（公告）日：2007-03-15

  [EN] The present invention pertains to certain 1,5-substituted-1H-tetrazole compounds that, inter alia, inhibit 11ß- hydroxysteroid dehydrogenase type 1 (11ß-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, bothin vitro and in vivo, to inhibit 11ß-hydroxysteroid dehydrogenase type 1; to treat conditions that are ameliorated by the inhibition of 11ß-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes conditions such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS conditions such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
  [FR] La présente invention concerne certains composés 1H-tétrazole 1,5 substitués qui, notamment, inhibent la 11ß-hydroxystéroïde déshydrogénase de type 1(11ß-HSD1). Cette invention concerne également des compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions, tant in vitro qu'in vivo, afin d'inhiber la 11ß-hydroxystéroïde déshydrogénase de type 1; afin de traiter des pathologies atténuées par l'inhibition de la 11ß-hydroxystéroïde déshydrogénase de type 1; afin de traiter le syndrome métabolique, qui inclut des affections telles que le diabète de type 2 et l'obésité, ainsi que des pathologies associées, notamment l'insulinorésistance, l'hypertension, les troubles lipidiques et les pathologies cardiovasculaires telles que les maladies cardiaques ischémiques (coronariennes) ; afin de traiter des affections du SNC telles que le déficit cognitif léger et la démence précoce, y compris la maladie d'Alzheimer; etc.